iShares Biotechnology ETF (NASDAQ:IBB) Shares Purchased by Fidelis Capital Partners LLC

Fidelis Capital Partners LLC raised its position in iShares Biotechnology ETF (NASDAQ:IBB) by 49.8% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,844 shares of the financial services provider’s stock after purchasing an additional 1,610 shares during the quarter. Fidelis Capital Partners LLC’s holdings in iShares Biotechnology ETF were worth $669,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Future Financial Wealth Managment LLC acquired a new position in iShares Biotechnology ETF during the first quarter valued at approximately $27,000. Bbjs Financial Advisors LLC acquired a new position in shares of iShares Biotechnology ETF during the 2nd quarter valued at $31,000. Pacifica Partners Inc. boosted its position in iShares Biotechnology ETF by 118.2% during the 1st quarter. Pacifica Partners Inc. now owns 240 shares of the financial services provider’s stock worth $33,000 after purchasing an additional 130 shares during the period. YHB Investment Advisors Inc. acquired a new stake in iShares Biotechnology ETF in the 1st quarter valued at $37,000. Finally, Mather Group LLC. purchased a new position in iShares Biotechnology ETF in the first quarter valued at about $57,000. 62.45% of the stock is owned by institutional investors and hedge funds.

iShares Biotechnology ETF Stock Down 1.0 %

Shares of NASDAQ IBB opened at $147.98 on Monday. iShares Biotechnology ETF has a 1-year low of $111.83 and a 1-year high of $150.57. The business has a 50-day moving average of $145.80 and a 200-day moving average of $138.62.

About iShares Biotechnology ETF

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.